Jan Aushadhi Encyclopedia Part 2: Economics & The “Brand Tax” Elimination

The most common question about Jan Aushadhi is: “How can it be so cheap?” The answer lies in a radical restructuring of how a medicine travels from the factory to the patient.

---

1. The Myth of the “Cheap” Drug

In the pharmaceutical world, “cheap” does not mean poor quality. In fact, the cost of manufacturing a high-quality chemical molecule (the Active Pharmaceutical Ingredient or API) is relatively low. The price of a branded medicine is inflated by overheads, not the actual chemical ingredients.

2. The Components of the “Brand Tax”

When you buy a branded medicine (e.g., a popular brand of Atorvastatin for ₹150), you are paying for:

• R&D Recovery: The original patent holder recovering billions in research costs (even if the patent expired 20 years ago, the brand name retains the premium).
• Medical Representatives (MRs): The cost of thousands of sales staff visiting doctors daily to influence prescriptions.
• Marketing & Gifting: Sponsorships for medical conferences, promotional materials, and advertisements.
• High Retail Margins: Providing 30-40% margins to private stockists and chemists to ensure they push that specific brand.

Jan Aushadhi eliminates 100% of these “Brand Tax” components.

---

3. The 50% Pricing Rule: A Non-Negotiable Cap

The PMBI follows a strict mathematical pricing policy to ensure that Jan Aushadhi medicines remain the most affordable in the country.

Rule: The Maximum Retail Price (MRP) of a PMBJP medicine is capped at 50% of the average price of the top three branded equivalents in the market.

Example Case Study (Heart Medicine):

• Brand A (Top Seller): ₹200
• Brand B: ₹180
• Brand C: ₹160
• Average of Top 3: ₹180
• Jan Aushadhi Cap: ₹90 (Maximum)

In reality, because PMBI procures at massive scale without any marketing effort, the actual Jan Aushadhi price often ends up being ₹20 or ₹30, representing a 70-80% saving over the cap itself.

---

4. Bulk Procurement & The Power of Volume

PMBI uses a Transparent Open Tender system.

1. Massive Demand: By consolidating the needs of 10,000+ stores, PMBI places orders for millions of strips at once.
2. No Sales Effort for Manufacturers: A pharmaceutical company doesn’t need to hire a single MR or run a single ad to sell to Jan Aushadhi. They simply win the tender and ship the goods. This allows them to offer PMBI their lowest possible “Ex-Factory” price.
3. Low Administrative Overhead: PMBI operates with a lean structure, focusing on logistics rather than profit-seeking.

5. Direct-to-Store Supply Chain

The private market has multiple layers:

• Manufacturer $\rightarrow$ C&F Agent $\rightarrow$ Super Stockist $\rightarrow$ Wholesaler $\rightarrow$ Retailer.

Each layer adds a 5-15% margin. Jan Aushadhi cuts the chain:

• Manufacturer $\rightarrow$ PMBI Warehouse $\rightarrow$ Jan Aushadhi Kendra.

By removing 2-3 layers of middlemen, another 20-30% of the cost is instantly eliminated.

Summary

The “cheapness” of Jan Aushadhi is a result of economic efficiency, not a compromise in science. It is the pharmaceutical equivalent of “Direct-to-Consumer” (DTC) models, where the consumer benefits from the removal of inefficient marketing and distribution cycles.

In Part 3, we address the ultimate concern: Quality. How do we know these low-cost molecules are actually working?

---

Next: Part 3 - Quality Without Compromise: The NABL Testing Protocol